StonvexLoading…
StonvexStonvexStonvexCore line items from CHDN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $663.00M | $2.93B | $2.26B | $1.58B |
Operating Income | $143.00M | $683.80M | $560.30M | $462.30M |
Net Income | $83.00M | $383.00M | $331.70M | $216.90M |
EPS (Diluted) | $1.16 | $5.29 | $4.55 | $3.98 |
Total Assets | $7.49B | $7.49B | $7.45B | $7.38B |
Total Liabilities | $6.34B | $6.43B | $6.38B | $6.31B |
Cash & Equivalents | $200.00M | $201.00M | $180.50M | $182.40M |
Free Cash Flow OCF − CapEx | $276.00M | $699.60M | $620.90M | $454.60M |
Shares Outstanding | 70.00M | 69.60M | 72.50M | 73.30M |